報價延遲最少15分鐘:2025/09/15 15:48 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.09
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.06/7.16
|
|
企業價值
1.97B
|
| 資產負債 |
|
每股賬面淨值
7.37
|
| 現金流量 |
|
現金流量率
0.14
|
| 損益表 |
|
收益
631.45M
|
|
每股收益
17.35
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/15 15:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
